Key Points
- Director James Foster sold 33,561 CRL shares for approximately $10.1 million at $300 per share, reducing his direct ownership by 51.5% to 31,596 shares. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Charles River exceeded quarterly expectations with $3.02 in EPS versus the $2.77 consensus and $1 billion in revenue, although revenue declined 2.7% year over year and the company reported a negative net margin.
- Analyst sentiment remains positive, with 12 Buy ratings and an overall “Moderate Buy” consensus, though the average price target of $255.65 is below the reported share price near its 52-week high.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) Director James Foster sold 33,561 shares of the company's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $9,478,800. This represents a 51.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Price Performance
CRL opened at $296.94 on Friday. The company has a market capitalization of $14.18 billion, a P/E ratio of -61.22, a PEG ratio of 3.06 and a beta of 1.38. The company has a 50-day moving average of $243.93 and a 200-day moving average of $196.64. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $303.31.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.33 EPS for the current fiscal year.
Analyst Ratings Changes
CRL has been the topic of a number of research reports. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a report on Monday, August 10th. Barclays reaffirmed an "overweight" rating and issued a $300.00 price target on shares of Charles River Laboratories International in a report on Wednesday, August 5th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a report on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of "Moderate Buy" and an average target price of $255.65.
Get Our Latest Report on Charles River Laboratories International
Institutional Investors Weigh In On Charles River Laboratories International
Large investors have recently made changes to their positions in the company. Cardinal Capital Management boosted its position in shares of Charles River Laboratories International by 0.6% during the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company's stock worth $2,180,000 after buying an additional 62 shares during the period. Glenmede Trust Co. NA boosted its position in Charles River Laboratories International by 2.8% during the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company's stock worth $467,000 after acquiring an additional 73 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company's stock worth $1,260,000 after purchasing an additional 80 shares in the last quarter. Syon Capital LLC increased its holdings in shares of Charles River Laboratories International by 2.4% during the second quarter. Syon Capital LLC now owns 3,547 shares of the medical research company's stock valued at $804,000 after purchasing an additional 83 shares during the period. Finally, Advisory Services Network LLC raised its stake in shares of Charles River Laboratories International by 2.6% during the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company's stock valued at $505,000 after purchasing an additional 83 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.
Trending Headlines about Charles River Laboratories International
Here are the key news stories impacting Charles River Laboratories International this week:
- Positive Sentiment: Analysts raised longer-term earnings expectations. Zacks Research increased its FY2026 EPS estimate to $11.15 from $10.91, FY2027 to $12.49 from $12.11, and FY2028 to $13.82 from $13.01. Estimates were also raised for Q2 2027, Q3 2027, and Q1 2028, suggesting improving expectations for Charles River’s earnings outlook.
- Positive Sentiment: Global vaccine collaboration could support future demand. Medigen has partnered with Charles River in an effort to take an enterovirus vaccine global, potentially creating additional work for the company’s contract research and development services. Medigen links up with Charles River in push to take enterovirus vaccine global
- Neutral Sentiment: Wall Street sentiment remains a key focus. A recent report examines whether analysts are bullish or bearish on CRL, reflecting investor attention following the stock’s sharp advance and its elevated valuation. Is Wall Street bullish or bearish on Charles River Laboratories stock?
- Negative Sentiment: Director James C. Foster sold a substantial stake. Foster sold 33,561 shares for approximately $10.1 million at $300 per share, reducing his direct holdings by 51.5%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which lessens its significance as a discretionary bearish signal but may still weigh on sentiment. SEC insider transaction filing
- Negative Sentiment: Some near-term estimates were trimmed. Zacks lowered forecasts for Q3 and Q4 2026 EPS and Q1 2027 EPS slightly, while also reducing its Q4 2027 estimate. The revisions indicate modest near-term uncertainty despite the stronger full-year and longer-term outlook.
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
